Latest / DDReg Knowledge Capsule / South Korea KDMF Requirements for Imported APIs

Transcript

South Korea KDMF Requirements for Imported APIs · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to the DD Reg Knowledge Capsule. So I want
• 0:04
  Speaker 1: you to imagine the scenario for a moment.
• 0:06
  Speaker 2: Okay.
• 0:07
  Speaker 1: You have a multi-million dollar shipment of this highly purified
• 0:11
  Speaker 1: active pharmaceutical ingredient, an API, right? Right. And it just
• 0:15
  Speaker 1: hit the port of Busan in South Korea. The science
• 0:19
  Speaker 1: is flawless. It's been approved in the U.S. It's actively
• 0:22
  Speaker 1: being used in Europe.
• 0:24
  Speaker 2: Sounds like a success story so far.
• 0:25
  Speaker 1: You'd think so. I mean, you'd expect it to be
• 0:27
  Speaker 1: moving to a manufacturing facility, to be pressed into life-saving tablets,
• 0:31
  Speaker 1: but instead, it is just sitting in customs.
• 0:35
  Speaker 2: Oh, wow.
• 0:36
  Speaker 1: Yeah, it's indefinitely halted. And why? Because your local importer
• 0:40
  Speaker 1: didn't file a specific site registration document that aligns perfectly with, like,
• 0:44
  Speaker 1: a tiny modification you made to your manufacturing process three
• 0:47
  Speaker 1: months ago.
• 0:48
  Speaker 2: Yeah, and, you know, it is a scenario that plays
• 0:50
  Speaker 2: out far more often than people realize. It really perfectly
• 0:53
  Speaker 2: illustrates the... The central friction of international pharmaceutical expansion.
• 0:57
  Speaker 1: Because everyone just assumes the science speaks for itself, right?
• 1:00
  Speaker 2: Exactly. There is this deeply ingrained assumption in the industry
• 1:04
  Speaker 2: that if your API meets the highest global quality specifications,
• 1:07
  Speaker 2: those technical specs will just act as a universal passport.
• 1:10
  Speaker 1: Right.
• 1:11
  Speaker 2: But as your example highlights, breaking into South Korea requires
• 1:14
  Speaker 2: dismantling that assumption entirely.
• 1:17
  Speaker 1: And that is exactly our mission for this deep dive.
• 1:20
  Speaker 1: We are taking a really comprehensive guide provided by DD
• 1:23
  Speaker 1: Reg Pharma. focusing heavily on the KDMF.
• 1:26
  Speaker 2: The Korea Drug Master File.
• 1:27
  Speaker 1: Right, the KDMF. And we are going to shortcut your
• 1:30
  Speaker 1: way to being completely well-informed on South Korean market entry planning.
• 1:34
  Speaker 2: Which is so critical right now.
• 1:35
  Speaker 1: It really is. We're unpacking how to navigate the Ministry
• 1:38
  Speaker 1: of Food and Drug Safety, the MFDS, without getting lost
• 1:41
  Speaker 1: in translation or, you know, caught in these massive compliance gaps,
• 1:46
  Speaker 1: especially given the new regulatory updates that took effect in
• 1:49
  Speaker 1: December 2024.
• 1:50
  Speaker 2: Entering South Korea demands a flawless, Korea-specific regulatory strategy. I mean,
• 1:55
  Speaker 2: you really have to be intentional. The MFDS has evolved
• 1:59
  Speaker 2: its framework, particularly regarding how they assess good manufacturing practices,
• 2:03
  Speaker 2: or GMP, for imported APIs.
• 2:06
  Speaker 1: So you can't just coast on your previous wins.
• 2:09
  Speaker 2: Not at all. If you are an overseas manufacturer, you
• 2:11
  Speaker 2: cannot simply rely on the momentum of your past global approvals.
• 2:15
  Speaker 2: You have to understand the specific architectural logic of the
• 2:18
  Speaker 2: Korean system.
• 2:19
  Speaker 1: Because the margin for administrative error is, what, basically zero?
• 2:22
  Speaker 2: Practically zero, yeah.
• 2:24
  Speaker 1: Okay, so before we even get into the mechanics of
• 2:27
  Speaker 1: how to register a KDMF and comply with these new
• 2:30
  Speaker 1: December 2024 updates, we need to establish what this actually is.
• 2:34
  Speaker 2: Right, the basics.
• 2:35
  Speaker 1: And more importantly, if the API you're working with even
• 2:38
  Speaker 1: requires one in the first place.
• 2:39
  Speaker 2: Well, a drug master file, conceptually, is a regulatory mechanism
• 2:44
  Speaker 2: designed to solve a very specific business and legal problem.
• 2:47
  Speaker 1: Which is?
• 2:48
  Speaker 2: It allows the regulatory body, so the MFDS in this context,
• 2:53
  Speaker 2: to evaluate critical, highly confidential information about how an API
• 2:57
  Speaker 2: is manufactured.
• 2:58
  Speaker 1: Without spilling all the secrets.
• 2:59
  Speaker 2: Exactly. It does this without forcing the API manufacturer to
• 3:03
  Speaker 2: hand over all their proprietary trade secrets to the company
• 3:06
  Speaker 2: that's making the finished pharmaceutical product.
• 3:08
  Speaker 1: Okay, let's unpack this. It's basically like a nightclub VIP pass.
• 3:13
  Speaker 2: A VIP pass.
• 3:13
  Speaker 1: Right?
• 3:14
  Speaker 2: I like that.
• 3:14
  Speaker 1: Like the KDMF protects your private section. Your complex chemical syntheses,
• 3:19
  Speaker 1: your proprietary crystallization processes, that's all in the VIP area.
• 3:23
  Speaker 2: Right, right.
• 3:23
  Speaker 1: But it still lets the club owner, which is the MFDS,
• 3:27
  Speaker 1: step behind the velvet rope to verify that everything is
• 3:29
  Speaker 1: safe and compliant. You never have to show the finished
• 3:32
  Speaker 1: product manufacturer, the general admission crowd, exactly how you engineer
• 3:36
  Speaker 1: the ingredient.
• 3:37
  Speaker 2: That is exactly the dynamic. It creates a completely secure
• 3:41
  Speaker 2: regulatory foundation. Yeah. Once the API is registered via the KDMF,
• 3:46
  Speaker 2: That secure data can be referenced to support a Korean
• 3:49
  Speaker 2: finished product application. So keeping your commercial sensitivity completely intact.
• 3:53
  Speaker 1: But as you alluded to, figuring out your market eligibility
• 3:57
  Speaker 1: is step one because not everyone needs the VIP pass.
• 4:00
  Speaker 1: If you're just an inactive excipient, you're general admission, right?
• 4:04
  Speaker 2: Yep, that's true. Knowledge is most valuable when it's applied properly.
• 4:07
  Speaker 2: And you definitely don't want to waste time on unnecessary
• 4:10
  Speaker 2: paperwork if you're in an excluded category.
• 4:13
  Speaker 1: So who is actually mandated to go through this specific
• 4:16
  Speaker 1: KDMF process under the current framework?
• 4:18
  Speaker 2: The mandate applies strictly to certain new substance APIs intended
• 4:23
  Speaker 2: for use in new drugs. Okay. It also applies to
• 4:27
  Speaker 2: APIs that are explicitly listed in the applicable MFDS annexes,
• 4:31
  Speaker 2: and that is a constantly updating roster, so you really
• 4:34
  Speaker 2: have to monitor it.
• 4:35
  Speaker 1: So it's not a static list?
• 4:37
  Speaker 2: No, not at all. Furthermore, it covers human placenta-derived APIs
• 4:41
  Speaker 2: and specified categories of herbal medicine APIs.
• 4:44
  Speaker 1: Why those specifically?
• 4:45
  Speaker 2: Well, both of those carry really unique risk profiles regarding
• 4:49
  Speaker 2: contamination and consistency, so they want to keep a very
• 4:51
  Speaker 2: close eye on them.
• 4:53
  Speaker 1: Okay, so new substances, specifically listed ingredients, and high-risk biological origins,
• 4:58
  Speaker 1: like placenta or specific herbs.
• 5:01
  Speaker 2: Exactly. So.
• 5:02
  Speaker 1: If I'm manufacturing a standard excipient, say, just a binding
• 5:05
  Speaker 1: agent or a preservative that doesn't actually provide a therapeutic effect,
• 5:09
  Speaker 1: I'm assuming I don't need to build this massive KDMF dossier.
• 5:12
  Speaker 2: Correct. Pharmacologically inactive ingredients are explicitly excluded.
• 5:17
  Speaker 1: That makes sense.
• 5:18
  Speaker 2: If your ingredient isn't the active driver of the drug's
• 5:21
  Speaker 2: therapeutic effect, you are exempt from this specific pathway. But
• 5:25
  Speaker 2: the exclusions actually go further than just excipients.
• 5:28
  Speaker 1: Oh, really?
• 5:29
  Speaker 2: Yeah. If you are working with orphan drugs, biologicals, cell therapies,
• 5:33
  Speaker 2: gene therapies, or radiopharmaceuticals, you also fall outside the KDMF scope.
• 5:39
  Speaker 1: Wait, I understand the excipient exclusion, but excluding biologicals and
• 5:43
  Speaker 1: gene therapies seems kind of counterintuitive.
• 5:46
  Speaker 2: I can see why you'd think that.
• 5:47
  Speaker 1: Aren't those the most complex and high-risk products on the
• 5:50
  Speaker 1: market right now? Why wouldn't the MFDS want a master
• 5:53
  Speaker 1: file on them?
• 5:54
  Speaker 2: It is precisely because of their complexity that they are
• 5:57
  Speaker 2: excluded from the standard KDMF system. I mean, biologicals are grown,
• 6:02
  Speaker 2: not synthesized. Oh, right. Their molecular structures are vastly larger
• 6:07
  Speaker 2: and inherently more variable than small molecule chemical APIs.
• 6:11
  Speaker 1: So a standard file just doesn't cut it.
• 6:13
  Speaker 2: Exactly. Because the manufacturing process of a biologic is so
• 6:16
  Speaker 2: inextricably linked to the final product safety, like way more
• 6:21
  Speaker 2: so than a traditional chemical. The MFDS requires them to
• 6:25
  Speaker 2: go through entirely distinct, highly bespoke biological regulatory pathways.
• 6:30
  Speaker 1: Okay.
• 6:31
  Speaker 2: A standard master file format simply cannot capture the dynamic
• 6:34
  Speaker 2: variables of living cell cultures.
• 6:35
  Speaker 1: That makes perfect sense.
• 6:37
  Speaker 2: The tool has to match the complexity of the material.
• 6:39
  Speaker 1: Precisely. So assuming you are a foreign manufacturer of a
• 6:43
  Speaker 1: new synthetic small molecule API, and you know for a
• 6:47
  Speaker 1: fact you need a KDMF.
• 6:48
  Speaker 2: Okay, you're in.
• 6:49
  Speaker 1: The immediate temptation here, and the sources actually call this
• 6:52
  Speaker 1: out as a massive pitfall, is to look at the
• 6:54
  Speaker 1: documents you already have and just repurpose them. Yes.
• 6:58
  Speaker 2: The global copy-paste trap.
• 7:00
  Speaker 1: Right. Because you might have a U.S. DMF approved by
• 7:03
  Speaker 1: the FDA, or a European ASMF, an active substance master file.
• 7:08
  Speaker 1: Or maybe you have a CEP, that Certificate of Suitability
• 7:11
  Speaker 1: from the European Directorate.
• 7:13
  Speaker 2: Which are all rigorous standards.
• 7:14
  Speaker 1: Exactly. You have thousands of pages of approved data. You
• 7:18
  Speaker 1: just Gather the PDFs and send them to Korea, right?
• 7:21
  Speaker 2: And that is the single most common reason foreign manufacturers
• 7:24
  Speaker 2: face catastrophic delays in South Korea. What's fascinating here is
• 7:28
  Speaker 2: that having a USDMF or a European ASMF is a
• 7:31
  Speaker 2: fantastic technical foundation.
• 7:33
  Speaker 1: Sure, it proves the science works.
• 7:35
  Speaker 2: It proves your data exists. But treating those documents as
• 7:38
  Speaker 2: a one-to-one substitute for a KDMF is a fundamental miscalculation.
• 7:42
  Speaker 1: See, I'll push back on that, playing devil's advocate for
• 7:45
  Speaker 1: you listening.
• 7:46
  Speaker 2: Go ahead.
• 7:46
  Speaker 1: Chemical science is chemical science. A molecule of ibuprofen synthesized
• 7:50
  Speaker 1: in a lab in New Jersey is exactly the same
• 7:53
  Speaker 1: as a molecule synthesized in Munich or Seoul.
• 7:56
  Speaker 2: Chemically speaking, yes.
• 7:58
  Speaker 1: So if the U.S. FDA, which is notoriously strict, has
• 8:02
  Speaker 1: rigorously reviewed my stability data and impurity profiles and cleared
• 8:07
  Speaker 1: my ASMF, why is the MFDS making me jump through
• 8:10
  Speaker 1: identical hoops?
• 8:12
  Speaker 2: Because while the physical chemistry remains constant, The legal frameworks,
• 8:16
  Speaker 2: the historical context for risk, and the specific formatting requirements
• 8:20
  Speaker 2: do not.
• 8:21
  Speaker 1: It's a completely different legal language.
• 8:23
  Speaker 2: Exactly. Every sovereign regulatory body has its own distinct mandate
• 8:27
  Speaker 2: and risk assessments. Relying on an outdated global dossier is
• 8:31
  Speaker 2: listed in the sources as a primary gap that delays registration.
• 8:35
  Speaker 1: Can you give an example of how they might differ?
• 8:37
  Speaker 2: Sure. For example, the FDA might place a heavier emphasis
• 8:41
  Speaker 2: on a specific type of retrospective batch data, based on
• 8:44
  Speaker 2: an issue they had domestically, like 10 years ago.
• 8:46
  Speaker 1: Okay.
• 8:48
  Speaker 2: Whereas the MFDS might require prospective validation data presented in
• 8:52
  Speaker 2: a completely different matrix.
• 8:54
  Speaker 1: So I'm not just proving the science works, I'm proving
• 8:56
  Speaker 1: it works according to their specific legal language of safety.
• 8:59
  Speaker 2: Exactly. And this brings us directly to the December 2024
• 9:03
  Speaker 2: framework updates mentioned in the DD-REG guide.
• 9:05
  Speaker 1: Right, the new rules.
• 9:07
  Speaker 2: The MFDS introduced highly specific changes affecting how they conduct
• 9:11
  Speaker 2: GMP good manufacturing practices. assessments for imported APIs. If you
• 9:16
  Speaker 2: submit a U.S. dossier that was formatted three years ago,
• 9:20
  Speaker 2: it will completely fail to account for these newly implemented
• 9:22
  Speaker 2: Korean specificities.
• 9:24
  Speaker 1: Especially regarding manufacturing site compliance, right?
• 9:27
  Speaker 2: Yes, and evidence formatting.
• 9:29
  Speaker 1: And the formatting alone is an enormous hurdle, specifically regarding language.
• 9:33
  Speaker 1: The guide is very clear that you cannot simply submit
• 9:36
  Speaker 1: a thousand-page English dossier and expect the Korean reviewers to just, like,
• 9:40
  Speaker 1: parse through it.
• 9:41
  Speaker 2: No, the language requirements are an administrative gauntlet.
• 9:43
  Speaker 1: Wow.
• 9:44
  Speaker 2: If your original technical documents are in English, you are
• 9:47
  Speaker 2: legally required to provide a highly detailed, comprehensive Korean summary
• 9:52
  Speaker 2: of the key information.
• 9:53
  Speaker 1: And what if the dossier was originally prepared for the
• 9:56
  Speaker 1: Japanese or German market, so it's not even in English
• 9:58
  Speaker 1: to begin with?
• 9:59
  Speaker 2: Then the burden effectively doubles.
• 10:01
  Speaker 1: Oh no.
• 10:02
  Speaker 2: For non-English foreign languages, you require the full Korean summaries
• 10:06
  Speaker 2: and full certified translations of the entire document set.
• 10:09
  Speaker 1: And I'm guessing you can't just run this through standard
• 10:11
  Speaker 1: translation software.
• 10:12
  Speaker 2: Definitely not. Pharmaceutical translation is a highly specialized discipline. The
• 10:17
  Speaker 2: terminology must perfectly map to the specific glossary used by
• 10:21
  Speaker 2: the MFDS.
• 10:22
  Speaker 1: So precision is everything.
• 10:24
  Speaker 2: If your translation introduces even a slight ambiguity into your
• 10:28
  Speaker 2: impurity specifications, the reviewer won't ask for clarification. They will
• 10:31
  Speaker 2: simply halt the application. Ambiguity equals rejection.
• 10:37
  Speaker 1: Okay, so the copy-paste strategy is dead on a rifle.
• 10:40
  Speaker 1: We know we need a custom Korea-specific approach. We've done
• 10:44
  Speaker 1: the gap analysis between our USDMF and the KDMF requirements.
• 10:49
  Speaker 1: And we've hired specialized translators. Yep.
• 10:51
  Speaker 2: You're on the right track.
• 10:52
  Speaker 1: So how do we actually submit this? What does the
• 10:55
  Speaker 1: bureaucratic blueprint look like?
• 10:57
  Speaker 2: Well, the Korean framework generally outlines two practical routes for submission. Okay.
• 11:02
  Speaker 2: The first is a standalone API DMF registration. This is
• 11:06
  Speaker 2: where you submit your dossier independently of any specific finished
• 11:10
  Speaker 2: product application.
• 11:11
  Speaker 1: Which seems like a highly proactive strategy. You are getting
• 11:14
  Speaker 1: the API approved on its own merits, placing it on
• 11:17
  Speaker 1: a registered list. Right. So when a Korean finished product
• 11:20
  Speaker 1: manufacturer actually wants to buy your API, the regulatory friction
• 11:24
  Speaker 1: is already totally removed.
• 11:25
  Speaker 2: It is very proactive. And frankly, it makes you a
• 11:28
  Speaker 2: highly attractive supplier.
• 11:30
  Speaker 1: Definitely.
• 11:31
  Speaker 2: And the second route? The second route is an API
• 11:33
  Speaker 2: registration that is directly linked to a finished product application.
• 11:38
  Speaker 1: Okay. How does that work?
• 11:39
  Speaker 2: In this scenario, the MFDS reviews your API registration information
• 11:43
  Speaker 2: in direct connection with a specific pharmaceutical product approval that
• 11:47
  Speaker 2: a Korean partner is actively submitting. I see.
• 11:50
  Speaker 1: So it's a package deal.
• 11:51
  Speaker 2: Basically. The route you choose dictates the timeline and the
• 11:55
  Speaker 2: level of coordination required.
• 11:56
  Speaker 1: Regardless of the route, though, the actual dossier requirements are
• 12:00
  Speaker 1: incredibly dense. I mean, looking at the sources, we are
• 12:02
  Speaker 1: talking about comprehensive data on the manufacturing site and GMP evidence,
• 12:06
  Speaker 1: API identity and characteristics. The exact manufacturing process.
• 12:11
  Speaker 2: Specifications and analytical methods. Right.
• 12:13
  Speaker 1: Stability data, packaging, and batch data. It's massive.
• 12:17
  Speaker 2: They are building a complete 360-degree profile of not just
• 12:21
  Speaker 2: what the API is, but how robust and repeatable the
• 12:24
  Speaker 2: environment is that produces it.
• 12:26
  Speaker 1: Here's where it gets really interesting, though. Reading through the sources,
• 12:29
  Speaker 1: there's this critical layer regarding how that data is presented.
• 12:33
  Speaker 2: Yes, the internal alignments.
• 12:35
  Speaker 1: Exactly. A checklist isn't enough. You can't just say, yes,
• 12:38
  Speaker 1: we included the stability data. Yes, we included the manufacturing
• 12:41
  Speaker 1: process flow.
• 12:42
  Speaker 2: It's not a disconnected set of PDFs.
• 12:45
  Speaker 1: It's more like compiling a massive piece of software architecture.
• 12:48
  Speaker 1: Like if your process flow documentation, so the front end logic,
• 12:52
  Speaker 1: says your synthesis requires baking at 350 degrees, but your
• 12:56
  Speaker 1: stability testing package, the back end database, assumes 400 degrees,
• 13:01
  Speaker 1: the entire system crashes.
• 13:02
  Speaker 2: That's a great analogy.
• 13:03
  Speaker 1: The MFDS will catch that contradiction instantly. The document has
• 13:07
  Speaker 1: to agree with itself.
• 13:09
  Speaker 2: Internal inconsistency is the silent killer of global dossiers. When
• 13:13
  Speaker 2: companies try to quickly adapt a European file for Korea,
• 13:16
  Speaker 2: they often update one section to meet an MFDS standard,
• 13:20
  Speaker 2: but completely forget to trace how that update impacts the
• 13:23
  Speaker 2: data in three other sections.
• 13:25
  Speaker 1: And then it all falls apart.
• 13:27
  Speaker 2: The document must agree with itself flawlessly.
• 13:30
  Speaker 1: But even if your dossier is internally flawless, there is
• 13:34
  Speaker 1: a massive hidden roadblock in this bureaucratic blueprint, something that
• 13:38
  Speaker 1: catches incredibly sophisticated manufacturers entirely off guard.
• 13:42
  Speaker 2: You're referring to the Overseas Manufacturing Site Registration. Yes.
• 13:47
  Speaker 1: The KDMF registration, which gets your API technical data approved,
• 13:51
  Speaker 1: is a completely separate legal requirement from the registration of
• 13:54
  Speaker 1: the physical overseas facility where you actually make the API.
• 13:59
  Speaker 2: Which, if we connect this to the bigger picture, is
• 14:01
  Speaker 2: a huge point of failure.
• 14:03
  Speaker 1: Because logically, it feels strange. If I'm submitting a thousand-page
• 14:07
  Speaker 1: document about exactly how I manufacture this chemical, shouldn't the
• 14:11
  Speaker 1: physical building I make it in be covered by that
• 14:14
  Speaker 1: exact same process?
• 14:15
  Speaker 2: You would think so. But the Korean regulatory architecture separates
• 14:19
  Speaker 2: the product from the premises. Applicable overseas manufacturing sites must
• 14:23
  Speaker 2: be registered separately.
• 14:25
  Speaker 1: Okay.
• 14:26
  Speaker 2: And the critical variable here is that the foreign API
• 14:28
  Speaker 2: manufacturer cannot typically do this themselves.
• 14:31
  Speaker 1: Wait, really?
• 14:32
  Speaker 2: Under current Korean rules, the local Korean importer is legally
• 14:36
  Speaker 2: responsible for managing the relevant overseas site registration process.
• 14:41
  Speaker 1: So we've just introduced a highly complex triangle of communication here.
• 14:44
  Speaker 2: Exactly.
• 14:45
  Speaker 1: You have the foreign API maker sitting in Europe or
• 14:48
  Speaker 1: the U.S. holding all the highly guarded technical data. You
• 14:52
  Speaker 1: have the Korean product applicant who is trying to get
• 14:56
  Speaker 1: the finished drug approved. And you have the Korean importer
• 14:59
  Speaker 1: who holds the responsibility for registering the physical foreign site.
• 15:03
  Speaker 2: And if those three entities are not moving in total synchronization,
• 15:06
  Speaker 2: everything falls apart.
• 15:08
  Speaker 1: It's a coordination nightmare.
• 15:09
  Speaker 2: You can run into this agonizing, incredibly expensive scenario where
• 15:13
  Speaker 2: your KDMF technical dossier is pristine, translated flawlessly and perfectly
• 15:18
  Speaker 2: aligned with the December 2024 updates.
• 15:21
  Speaker 1: But the whole thing stops.
• 15:22
  Speaker 2: But the entire entry to the market is stalled because
• 15:25
  Speaker 2: the importer didn't file the site registration. Or file it
• 15:28
  Speaker 2: with information that contradicts your dossier.
• 15:30
  Speaker 1: And supportive Busan scenario we talked about at the very beginning.
• 15:33
  Speaker 2: Exactly.
• 15:34
  Speaker 1: So let's say you navigate the triangle perfectly. You coordinate
• 15:37
  Speaker 1: with your importer. You translate the technical data. Your internal
• 15:41
  Speaker 1: documents are consistent and you secure the KDMF approval.
• 15:44
  Speaker 2: Acceleration time.
• 15:45
  Speaker 1: Right. A lot of companies at this stage probably view
• 15:48
  Speaker 1: the approval as the finish line.
• 15:50
  Speaker 2: Which is a very dangerous mindset. Approval is merely the
• 15:53
  Speaker 2: entrance ticket. The real work is lifecycle management.
• 15:57
  Speaker 1: So what does this all mean for you listening? We
• 15:59
  Speaker 1: often treat regulatory approval like a graduation day, but it's
• 16:02
  Speaker 1: actually more like a marriage. You have to keep working
• 16:05
  Speaker 1: at it.
• 16:06
  Speaker 2: That's a very accurate way to frame it.
• 16:08
  Speaker 1: Or like an architectural blueprint. Once the building goes up,
• 16:11
  Speaker 1: the blueprint just goes in a drawer. But from the
• 16:14
  Speaker 1: DDREG guide, a KDMF is nothing like a static blueprint.
• 16:17
  Speaker 1: It's much more like a living software code base.
• 16:21
  Speaker 2: Every time you issue a patch, the whole system has
• 16:23
  Speaker 2: to be re-evaluated.
• 16:24
  Speaker 1: Right. Every time you tweak a line of code, you
• 16:27
  Speaker 1: have to ensure it hasn't broken the core functionality.
• 16:30
  Speaker 2: That is the exact reality of the MFDS framework. Your
• 16:34
  Speaker 2: KDMF must remain a perfectly accurate, living reflection of your
• 16:38
  Speaker 2: physical manufacturing reality.
• 16:40
  Speaker 1: So what triggers a review?
• 16:42
  Speaker 2: Well, if you change the manufacturing site, the core process,
• 16:45
  Speaker 2: your starting materials, your equipment scale, your batch sizes, or
• 16:49
  Speaker 2: even your analytical testing methods, all of those trigger mandatory
• 16:52
  Speaker 2: regulatory action in CREA.
• 16:54
  Speaker 1: Okay, but does it apply to things further down the
• 16:57
  Speaker 1: supply chain?
• 16:58
  Speaker 2: What do you mean?
• 16:58
  Speaker 1: Say I'm manufacturing an API in Europe, and I decide
• 17:02
  Speaker 1: to change the vendor who supplies me with a raw
• 17:05
  Speaker 1: base chemical. The final API still passes all my internal
• 17:09
  Speaker 1: quality checks. Do I really need to alert the MFDS
• 17:12
  Speaker 1: thousands of miles away?
• 17:13
  Speaker 2: Absolutely. And failing to do so is a massive liability.
• 17:17
  Speaker 1: Really? Just for a raw material vendor?
• 17:20
  Speaker 2: Yes, because changing a raw material supplier... can fundamentally alter
• 17:24
  Speaker 2: the microscopic impurity profile of your final API.
• 17:28
  Speaker 1: Ah, I didn't think of that.
• 17:29
  Speaker 2: Even if it still meets your broad specifications, the underlying
• 17:32
  Speaker 2: chemical fingerprint has changed. Depending on the exact nature of
• 17:35
  Speaker 2: the modification, the Korean regulations will demand either a rigorous
• 17:39
  Speaker 2: formal change registration or a specific reporting mechanism.
• 17:43
  Speaker 1: If a manufacturer decides to roll the dice and, you know,
• 17:46
  Speaker 1: not report that minor supplier change, what does the fallout
• 17:50
  Speaker 1: actually look like?
• 17:51
  Speaker 2: It results in a cascade failure.
• 17:54
  Speaker 1: A cascade failure. Walk me through that.
• 17:56
  Speaker 2: Let's trace it. You change your raw material supplier and
• 18:00
  Speaker 2: don't update your KDMF. Six months pass. Your client in Korea,
• 18:04
  Speaker 2: the finished product manufacturer, goes to the MFDS to submit
• 18:08
  Speaker 2: a new product application or a routine renewal.
• 18:10
  Speaker 1: And they reference your KDMF as their secure foundation. Right.
• 18:15
  Speaker 2: So the MFDS analyzes the new batches of the finished drug,
• 18:18
  Speaker 2: profiles the impurities and and immediately realizes there is a
• 18:22
  Speaker 2: stark discrepancy between the chemical reality of the API in
• 18:25
  Speaker 2: front of them and the registered data on file.
• 18:28
  Speaker 1: Because the chemical fingerprint no longer matches the VIP pass
• 18:32
  Speaker 1: they were issued.
• 18:32
  Speaker 2: Exactly. The MFDS halts the finished product submission immediately. Your
• 18:37
  Speaker 2: Korean client's multi-million dollar product launch is completely frozen. Oh, wow.
• 18:43
  Speaker 2: And they trace the fault directly back to your undisclosed
• 18:46
  Speaker 2: supplier change. Your credibility as a reliable global supplier is
• 18:50
  Speaker 2: completely destroyed, and the remediation process with the MFDS will
• 18:54
  Speaker 2: be incredibly hostile.
• 18:55
  Speaker 1: That is brutal. So when we talk about a successful
• 18:59
  Speaker 1: KDMF strategy, it starts months, if not years, before the
• 19:03
  Speaker 1: actual submission, and it literally never ends. Never. You have
• 19:06
  Speaker 1: to build a Korea-specific gap matrix from day one to
• 19:09
  Speaker 1: compare your existing global dossier against the current MFDS requirements.
• 19:14
  Speaker 1: You have to align your technical documents so the front-end
• 19:17
  Speaker 1: process matches the back-end data perfectly. And you have to
• 19:20
  Speaker 1: build an internal compliance culture that flags every single supply
• 19:24
  Speaker 1: chain change for a KDMF review.
• 19:27
  Speaker 2: Thorough preparation always beats remediation. That is the core takeaway here.
• 19:32
  Speaker 2: The KDMF cannot be treated as an isolated document formatting
• 19:35
  Speaker 2: exercise or like an administrative afterthought.
• 19:38
  Speaker 1: It's way too important for that.
• 19:40
  Speaker 2: It has to be an integrated pillar of your entire
• 19:42
  Speaker 2: manufacturing strategy.
• 19:44
  Speaker 1: Now, you mentioned earlier the December 2024 framework updates.
• 19:47
  Speaker 2: I did.
• 19:48
  Speaker 1: The DD-REG guide notes that while the precision required is
• 19:51
  Speaker 1: higher than ever, these updates actually simplified certain aspects of
• 19:55
  Speaker 1: imported API GMP assessments.
• 19:57
  Speaker 2: They did, yes.
• 19:58
  Speaker 1: They streamlined the formatting requirements for specific compliance evidence, and crucially,
• 20:03
  Speaker 1: they shortened the stated processing period for the relevant review routes.
• 20:07
  Speaker 1: It sounds like the MFDS is making a concerted effort
• 20:09
  Speaker 1: to make the regulatory environment more efficient.
• 20:12
  Speaker 2: They are. And this raises a really fascinating dynamic for
• 20:15
  Speaker 2: the broader Asian pharmaceutical market.
• 20:17
  Speaker 1: How so?
• 20:18
  Speaker 2: Well, the December 2024 updates were clearly designed to reduce
• 20:22
  Speaker 2: unnecessary bureaucratic friction, assuming, of course, your documentation is flawless. Right.
• 20:27
  Speaker 1: Big assumption.
• 20:28
  Speaker 2: But by shortening the stated processing timelines and streamlining the
• 20:31
  Speaker 2: GMP assessment pathways... the MFDS has effectively lowered the time-to-market
• 20:36
  Speaker 2: barrier for foreign imports.
• 20:38
  Speaker 1: Meaning, if you actually understand the system and do the
• 20:41
  Speaker 1: gap analysis correctly, you can get into South Korea much
• 20:45
  Speaker 1: faster than you could a year ago.
• 20:46
  Speaker 2: Exactly. And here is something for you to mull over
• 20:50
  Speaker 2: as we wrap up this analysis.
• 20:51
  Speaker 1: Okay, let's hear it.
• 20:53
  Speaker 2: With these shortened processing periods reducing the historical friction of entry,
• 20:57
  Speaker 2: are we about to see a sudden, aggressive influx of
• 20:59
  Speaker 2: highly agile, well-prepared foreign API manufacturers flooding into the South
• 21:04
  Speaker 2: Korean market?
• 21:05
  Speaker 1: That's a very real possibility.
• 21:07
  Speaker 2: And if that happens, how will the domestic Korean API suppliers,
• 21:11
  Speaker 2: who have traditionally enjoyed the buffer of a slow, complex
• 21:14
  Speaker 2: import process, handle that new accelerated wave of global competition?
• 21:19
  Speaker 1: Wow.
• 21:19
  Speaker 2: The regulatory gate has been optimized, and it could entirely
• 21:23
  Speaker 2: shift the balance of the supply chain in the region.
• 21:25
  Speaker 1: That is a massive strategic implication. You streamline the paperwork
• 21:29
  Speaker 1: to make the system more efficient. And inadvertently, you might
• 21:32
  Speaker 1: completely rewrite the competitive landscape of an entire country's pharmaceutical industry.
• 21:38
  Speaker 2: It's all connected.
• 21:39
  Speaker 1: It just proves that regulatory affairs isn't just about compliance.
• 21:42
  Speaker 1: It is pure business strategy. You have to know exactly
• 21:46
  Speaker 1: how to align your data to get past the MFDS
• 21:50
  Speaker 1: because the line of competitors outside is moving faster than ever.
• 21:53
  Speaker 1: Thank you for joining us on this deep dive. Stay
• 21:56
  Speaker 1: curious and keep exploring the sources.